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Background: Erectile dysfunction is prevalent in men over 40 years, affecting their quality of life and that of their
partners. The aims of this study were:
a) To evaluate the internal reliability of the male erectile dysfunction specific quality of life (MED-QoL) scale and
explore its factor structure.
b) To evaluate the effect of simvastatin on subscales of the MED-QoL in men over forty years with erectile dysfunction.
Methods: This is a double blind randomised controlled trial of 40 mg simvastatin or placebo given once daily for
six months to men over forty years with untreated erectile dysfunction, who were not at high cardiovascular risk
and were not on anti-hypertensive or lipid-lowering medication. 173 eligible men were recruited from 10 general
practices in East of England. Data were collected at two points over 30 weeks.
We report on the factor structure of MED-QoL, the internal reliability of the scale and the derived subscales, and the
effect of simvastatin on MED-QoL subscales.
Results: An initial analysis of the MED-QoL items suggested that a number of items should be removed (MED-QoL-R).
Exploratory factor analysis identified three subscales within the MED-QoL-R which accounted for 96% of the variance,
related to feelings of Control, initiating Intimacy, and Emotional response to erectile dysfunction. The alpha value for
the revised scale (MED-Qol-R) was >0.95 and exceeded .82 for each subscale. Regression analysis showed that patients
in the placebo group experienced a significantly reduced feeling of Control over erectile dysfunction than those in the
statin group. Those in the placebo group had significantly lower Emotional response than those in the statin group at
the close of trial, but there was no significant treatment effect on Intimacy.
Conclusions: Our revised MED-QoL-R identified three subscales. Secondary analysis showed a significant improvement
in sexual health related quality of life, specifically in relation to perception of control and emotional health in men with
untreated erectile dysfunction given 40 mg simvastatin for six months.
Trial registration: Current Controlled Trials ISRCTN66772971.
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Erectile dysfunction (ED) is the consistent inability to
achieve or maintain an erection that is sufficient for sat-
isfactory sexual intercourse. Although ED affects sexual
and mental health [1,2], the rates of consultation for ED
remain low [3,4] and not all patients respond to Sildena-
fil and other phosphodiesterase inhibitors [5]. We re-
ported the results of a randomised controlled trial (RCT)
evaluating the effectiveness and cost effectiveness of sim-
vastatin therapy in men with ED in men with untreated
ED, but without significant cardiovascular risk factors [6].
The lipid lowering drug simvastatin was chosen for this
study because ED shares risk factors with cardiovascular
disease (CVD) [7-11]. It is associated with high total and
low density lipoprotein cholesterol [12-14] and endothelial
dysfunction.
There is a consensus that ED is either a predictor of
future CVD or an early marker of silent atherosclerotic
cardiovascular disease [9,10]. Small scale studies have in-
dicated that atorvastatin can reduce ED and improve
sexual function [12,15] but to date, there is no evidence
to suggest that statins improve sexual health related
quality of life in men with untreated ED.
In our previously published trial [6], there was a non-
significant change in erectile function due to simvastatin
treatment, although patients with more severe ED at
baseline showed a larger improvement than patients
with mild/moderate ED. However, simvastatin signifi-
cantly improved the male ED-specific quality of life (MED-
QoL), LDL cholesterol and reduced future cardiovascular
risk [6]. It remains unclear why the MED-QoL improved
significantly with only a small effect on erectile function, as
the sexual encounter profile data showed nonsignificant
treatment effect on satisfaction or success.
The MED-QoL scale has not been widely used, and
there are few publications addressing the measurement
of sexual health related quality of life at all using the
MED-QoL. Only one paper has published any evidence
of the scale reliability or validity using a sample of 69
men [16]. The current analysis aims to evaluate the in-
ternal reliability of the MED-QoL scale, its factor struc-
ture, and the extent any identified factors show drug
related changes.
Methods
This is a secondary analysis of data from a double blind
RCT comparing treatment with simvastatin or placebo
on ED conducted in ten general practices in the East of
England. The study design methods and analysis for the
main study have been published previously [6,17]. The
study protocol was approved by the Essex 1 Research
Ethics Committee and clinical trial authorisation was ob-
tained from the UK Medicines and Healthcare Products
Regulatory Agency.Main trial study design
Patients
173 eligible men aged forty years and over with un-
treated ED (score < 22 on the IIEF-5 (International Index
of Erectile Function)), and no other cardiovascular risk
factors were randomised to receive 40 mg simvastatin or
placebo once daily for six months. Exclusions were based
on participants’ medical and drug history and those con-
sidered by the GP to be unsuitable, such as significant
CVD risk requiring statin treatment.
Study design
Randomization to active simvastatin or placebo was on a
1:1 basis and was computer-generated at the Clinical Tri-
als Co-ordinating Centre. Data were collected at baseline,
3 months and 6 months at assessment visits to the GP
clinic. At each visit, participants completed the IIEF-5
questionnaire, the MED-QoL and the EQ-5D [16,18,19].
Sexual encounter profile (SEP) diaries were completed
whenever an encounter occurred and were collected at
each assessment. All questionnaires were completed by
the men at the assessment visits in a private area, and
were given support if necessary to clarify any raised issues.
The MED-QoL questionnaire consists of 27 items. All
domains assess the effects of erectile dysfunction on the re-
spondents’ quality of life. The scale is based on 4 response
categories: ‘Not at all’, ‘A little’, ‘Quite a lot’ and ‘Very much’.
All 27 items in the MED-QoL are listed in Table 1.
Analysis
The primary analysis of the data from this trial has
been reported previously [6] using the original MED-
QoL questionnaire [16].
Secondary data analysis: MED-QoL scale reliability
A step wise approach was taken to evaluate the reliabil-
ity and factor structure of the MEDQoL scale. In the
first step (item reduction) items were evaluated for low
mean and a lack of endorsement, and low item-total cor-
relation. Identified items were examined to evaluate their
face validity before removal. In the second step an ex-
ploratory factor analysis was undertaken, with Varimax
rotation, and assessment of Kaiser-Meyer-Olkin (KMO)
sampling adequacy. Several factors (subscales) were
identified and the internal reliability of the items for
each factor was assessed. Items were again considered
for removal if the item-test statistics were weak, the fac-
tor loading was < .5 and if the KMO value indicated poor
model fit.
This process generated a reduced scale, removing 6 items
from the original MED-QoL scale. To avoid confusion we
named the revised version the MED-QoL-R. The scores
for each item in a subscale were summed and the subscale
score normalised (0-100). The identified subscales were
Table 1 Exploratory factor analysis of the MED-QoL
Factor Item* Factor 1 Factor 2 Factor 3 Cumulative
variance
Alpha Eigenvalue
1 (Control) 1. I feel sexually frustrated because of my erection
difficulties
0.638* 0.100 0.302 0.37 0.82 11.40
2. My problem makes me feel depressed 0.515* 0.119 0.443
3. I feel less of a man because of my problem 0.576* 0.296 0.448
4. I’ve lost confidence in my sexual ability 0.676* 0.349 0.211
5. I worry that I won’t be able to get or keep up an
erection
0.644* 0.294 0.302
7. I feel that I have lost control over my erections 0.681* 0.230 0.163
10. I worry about the future of my sex life 0.512* 0.417 0.327
12. I’m embarrassed about my problem 0.532* 0.236 0.480
16. I get less pleasure from life because of my
erection problem
0.502* 0.401 0.230
2 (Intimacy) 11. I’ve lost pleasure in sex 0.454 0.569* 0.070 0.69 0.85 1.54
17. I feel guilty about my erection problem 0.219 0.521* 0.478
18. I am afraid to “make the first move” with my
partner
0.316 0.665* 0.127
19. I worry that my partner blames herself for my
problem
0.062 0.540* 0.305
20. I worry that I’m letting my partner down 0.439 0.547* 0.427
21. I worry that I am not satisfying my partner
sexually
0.506 0.521* 0.217
22. I worry that we are going apart because of
my problem
0.257 0.605* 0.265
25. I worry that she thinks I don’t want her because
of my problem
0.194 0.690* 0.300
3 (Emotion) 6. My erection problem is always on my mind 0.459 0.302 0.506* 0.96 0.86 1.02
8. I blame myself for my problem 0.205 0.381 0.566*
9. I feel angry because of my problem 0.313 0.168 0.676*
13. I worry about being humiliated because of my
problem
0.263 0.288 0.626*
Excluded 14. I try to avoid having sex NA NA NA
15. I feel different from other men because of my
erection problem
NA NA NA
23. I worry that she is looking for someone else
because of my problem
NA NA NA
24. I feel that she blames me for my erection
problem
NA NA NA
26. I have trouble talking to her about my problem NA NA NA
27. My erection problem interferes with my daily
activities
NA NA NA
Scale total .96 .95
MED-QoL-R: male erectile dysfunction-specific quality of life revised scale. *Item numbers are based on the original MED-QoL scale. Factor analysis with varimax
rotation, excluding items 14, 15, 23, 24,26 and 27.
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changes in the total MED-QoL-R scores were determined
by particular subscales. Based on CONSORT guidelines,
the difference in the subscale scores at close of trial was
evaluated for each subscale in turn. A regression model
was used in which the outcome was the MED-QoL-R sub-scale score with treatment arm (statin vs. placebo) as a pre-
dictor. The outcome was adjusted for baseline ED severity
(and the interaction between severity and arm), baseline
testosterone, baseline 10 year cardiovascular risk, and the
baseline score for the subscale score. As some of the distri-
butions were positively skewed, log transformation was
Trivedi et al. BMC Urology 2014, 14:24 Page 4 of 7
http://www.biomedcentral.com/1471-2490/14/24applied to the data and bootstrapped confidence intervals
were estimated (with 3000 replications).
Results
In our trial, 173 patients were randomised, of which 131 pa-
tients completed some, and 113 completed all of the study
outcome measures [6]. 60 (34%) patients withdrew from
randomised treatment, but 18 of these patients continued to
complete the QoL measures. The proportion withdrawing
did not depend on study arm (χ2 (1) =0.5, p > 0.05).
Item numbers 15, 23, 24 and 27 of the 27 items had
low mean response values (1.60, 1.21, 1.48 & 1.15, respect-
ively), and had few responses in the highest category (<3%
'Very much'), indicative of a lack of endorsement of these
items. On this basis these items were removed.
Factor analysis
Following item reduction, the aim was to evaluate the
underlying factor structure. An initial factor analysis was
computed, excluding items 15, 23. 24 and 27 in order to
assess the structure within the scale. Alongside the fac-
tor analysis, the Kaiser-Meir-Olkin (KMO) was also
computed, assessing sampling adequacy of the overall
scale and each item for factor analysis. A low KMO indi-
cates that the item may not be relevant for the model
specified and therefore may be a basis to exclude the
item. For this model 3 factors with an Eigen value above
1 were found. Following the analysis, it was evident that
as well as having a low mean, item 14 and 26 had a low
KMO (0.88, 0.83, respectively). As item 14 already had a
relatively low mean, it was excluded from analysis along-
side items 15, 23,24 and 27 and the factor model was re-
evaluated (Table 1).
Reliability
Following factor analysis excluding items 14, 15, 23, 24
and 27, the internal reliability of each subscale was de-
termined using Cronbach’s Alpha. Item 26 had low
item-test reliability (0.58) compared to the rest of subscale
2 and was therefore removed from analysis. Subsequently,
factor analysis with varimax rotation was computed once
again, excluding items 14, 15, 23, 24, 26 and 27. The ana-
lysis yielded 3-factor model accounting for 96% of the
variance (Table 1).
The factor loadings for each item followed a pattern,
which we interpreted in the following way: Subscale (fac-
tor) 1 tended to belong to items which were related to
feelings of control (Control); the items in subscale 2
were concerned with difficulties in initiating intimate
contact (Intimacy); and the subscale 3 items were related
to emotional response to erectile dysfunction (Emotion).
Although there is a lot of overlap in the possible mean-
ing of subscales 1 and 3, the 4 highest loading items on fac-
tor 1 are related to feelings of control ([item 1] frustration,[item 4] confidence, [item 5] worry, and [item 7] loss of
control with the highest loading) rather than emotion, and
we have therefor interpreted the factor in that way.
Regression modelling: effectiveness on MED-QoL-R
subscales
Our initial analysis showed that the improvement in IIEF
due to statin treatment was not statistically different to
placebo, although patients with severe ED at baseline
showed a larger change than patients with mild/moder-
ate ED [6]. There was a statistically larger improvement
in total MED-QoL score for men on statin compared to
placebo (5% change in total scale score vs. 2%, z = 2.09,
p = .04), which was higher for men with severe ED (12%
change in total scale score vs. 5%, z = 4.52, p < 0.001). In
this analysis, using the MED-QoL-R, fitting a regression
model on each factor (Control, Intimacy and Emotion)
allows for an evaluation of changes in quality of life in
relation to the three subscales highlighted in the factor
analysis. Due to the distribution of the data, log transfor-
mations were applied to the outcome variables and the
exponentiated values were obtained to better explain the
linear relationship between variables (Table 2).
The regression model showed that for the Control sub-
scale, the level of control over their ED perceived by those
in the placebo group is significantly less than those in the
statin treatment group at the close of trial (z = -3.15, p <
0.005). Similarly, those in the severe ED group have a sig-
nificantly lower perception of control than those with
mild/moderate ED (z = - 1.97 p = 0.05).
Uniquely for this subscale, an increased number of re-
ported encounters between the couples at mid trial was
related to the observed advantage for perceived control
in men in the statin arm compared to the control arm.
Inclusion of the number of encounters did compromise
the number of patients entered into the model (n = 61)
but was a strong predictor of the outcome that a deci-
sion was made to include the number of encounters in
the model. The men excluded from the analysis (n = 47)
did not substantially differ from the men included in the
analysis (n = 61) on any of the major factors measured
(e.g. age, ED severity, treatment arm). For the other two
factors (Intimacy and Emotion) including the change in
the number of reported encounters from baseline to
close made no contribution to the model and was there-
fore not included.
The regression model fitted to the Intimacy subscale
showed that there was no significant effect of treatment
arm (z = -0.83 p > 0.05), ED severity (z = 0.66 p > 0.05),
baseline testosterone levels (z = -0.05 p > 0.05), baseline
cardiovascular risk (z = 1.31 p > 0.05) or an interaction
between treatment arm and ED severity (z = 0.14 p >
0.05) on the level of intimacy between the participant
and their partners.
Table 2 Regression models evaluating the effect of statin treatment on men with ED (statin vs placebo groups) for
each subscale (1-3) of the MED-QoL-R
N Proportionate difference
between study arms and
95% CI (regression model)
Mean values at close of trial (unadjusted values)
Severe ED Mild/moderate ED
Total MED-QoL-R 109 0.16 (0.01, 0.30) Statin 66.1 (58.1, 74.1) 70.7 (62.4, 78.9)
Placebo 58.3 (48.5, 68.2) 68.7 (61.6, 75.9)
Feeling of control (Subscale 1) 61# 0.40 (0.24, 0.53)* Statin 60.7 (52.3, 69.2) 67.2 (59.6, 74.9)
Placebo 51.6 (41.4, 61.9) 63.8 (56.6, 71.1)
Initiating intimacy (Subscale 2) 107 0.08 (0.12, 0.26) Statin 67.3 (58.1, 76.6) 72.8 (63.8, 81.8)
Placebo 62.7 (51.4, 74.1) 71.5 (64.0, 79.0)
Emotion response (Subscale 3) 104 0.25 (0.05, 0.41)* Statin 75.7 (65.8, 85.5) 74.2 (64.2, 84.1)
Placebo 64.4 (50.7, 78.0) 74.3 (65.9, 82.6)
MED-QoL-R: Revised male erectile dysfunction-specific quality of life. Column 3 provides the estimated proportionate difference between the study arms (1-exp
(model coefficient). Thus 0.4 represents a 40% lower value in the Placebo arm compared to the Statin arm. Regression models (bootstrapped n = 3000) for each
subscale were specified with treatment arm, ED severity, arm by severity, and baseline testosterone, cardiovascular risk, and time on treatment as variables.
#The number of patients who completed sufficient SEP Diaries (eg encounters) for inclusion in the analysis was lower than for most other outcomes-however for factor
1 (but not the other factors) the number of reported encounters was a very strong predictor of the outcome, and was therefore included in the model. *p < 0.05.
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that those in the placebo group have significantly lower
emotional state than those in the statin group (z = -2.35
p = 0.02) at study close. In general, the mild/moderate
patients reported a higher emotional state than those
with severe ED (z = -2.47 p = 0.01). There is a signifi-
cant interaction between treatment arm and severity
(z = 2.45 p = 0.01) indicating that patients in the severe
ED group benefited significantly more from treatment
than those in the mild to moderate ED groups.
Discussion
Our initial analysis showed that simvastatin significantly
improved the overall sexual health related quality of life
(MED-QoL), which was largest for men with severe ED,
despite the fact that the effect on erectile function was
not significant [6]. We identified three subscales within
MED-QOL that accounted for 96% of the variance relat-
ing to three quality of life characteristics: feelings of
Control, problems initiating Intimacy and Emotion re-
sponse to ED; named MED-QoL-R. Regression analysis
showed that for the Control subscale, those with severe ED
had significantly lower perception of control than those
with mild to moderate ED. Similarly, those treated with
statin had significantly improved perceptions of control at
the close of trial than those treated with placebo. Similar
results were found for subscale 3 (Emotion–excluding 4
outliers) where those treated with statin had a significantly
more positive emotional state at the close of trial than
those treated with placebo, although this is demonstrated
mostly within the severe ED group. Those with mild to
moderate ED had more positive emotional states than
those with severe ED. The effect of statins on mood is
equivocal [20] and it is possible that emotional improve-
ments are mediated via improvement in ED.Subscale 2, Intimacy, demonstrated no significant ef-
fect of either treatment arm or ED severity on level of
intimacy and neither this nor Emotion were influenced
by the number of encounters at midtrial. Uniquely, an
increased number of reported encounters is a significant
contributing factor in the improved perception of con-
trol over ED for men treated with simvastatin. This find-
ing supports previous studies which show that more
frequent erections improve erectile function, suggesting
that men with frequent erections are likely to have better
perception of control [21].
Our initial results showed no drug specific effect for
SEP erections or satisfaction, although there was an in-
crease in reported satisfaction over time for all partici-
pants and patients with mild/moderate ED reported
greater satisfaction than those with severe ED. However,
simvastatin showed no significant effect on SEP erec-
tions or satisfaction or reported frequency of encounters
or IIEF severity, although participants attempting inter-
course more than once a week on average reported
higher IIEF scores at close of trial [6]. Our overall find-
ings suggest that small changes in erectile function can
have a significant impact on the sexual health related
quality of life. This could be a result of an improvement
in both the perception of control and emotional do-
mains, but not a change in perceptions of intimacy.
The MED-QoL scale has previously not been exten-
sively used, or tested for reliability and validity. To our
knowledge the number of reported cases is less than 200
in total.
Undertaking an analysis of the reliability and factor
structure of the scale, and evaluating drug related
changes in the determined subscales from the same data
limits the external reliability of the reported analysis.
Care needs to be taken in interpreting these results until
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from a different population of men, demonstrating the
external reliability of our findings.
Our objective in undertaking this analysis was to fur-
ther evaluate the reliability and explore the factor struc-
ture of the MED-QoL scale, given that this had not been
done before, and not reported in an external patient
sample. Specifically we did not set out to create a brief
measure. The scale created, the MED-QoL-R, has 21
items, and represents the most robust (e.g. reliable) scale
suggested by the analysis of our data.
A number of scales to evaluate ED in men have been
developed over the past 20 years [22-26]. The choice of
the MED-QoL in our trial was based on familiarity of
the scale amongst the research team. The current study
offers additional evaluation of the MED-QoL in an exter-
nal patient sample with recognised statistical methods,
unlike most other scales developed. By undertaking this
study in a sample drawn from a clinical trial of men not
otherwise being treated, the analysis provides addition in-
formation about the reliability and underlying psycho-
logical dimensions of the MED-QoL, and provides a
revised version of the scale, the MED-QoL-R.
We may have seen larger changes and more benefit if
we had larger study sample, a longer treatment interval
and a more potent statin. The total MED-QoL-R scores
at close of trial showed that health related quality of life
significantly improves when treated with statin than with
placebo. Also, as found within the individual subscales,
those with mild to moderate ED have significantly higher
quality of life than those with severe ED. Overall the re-
sults demonstrate that sexual health related quality of
life in males with ED is significantly influenced by drug
treatment (statin compared to placebo) and by severity
of the ED. Specifically, both feelings of control and emo-
tional response to ED highlight this, compared to intim-
acy which is unaffected by treatment and severity of ED.
The study excluded patients with significantly high CVD
risk factors for ethical reasons. These were the men
most likely to benefit from the intervention. Erectile
function measured using the IIEF score defines ED prin-
cipally in physical terms (hardness, penetration success),
but does not take account of wider issues related to in-
timate relationships, which may or may not be related to
cardiovascular health. It is possible that improving car-
diovascular health has more general effects on sexual
health which leads to improved sexual interactions that
are not captured by the IIEF, but are captured by the
MED- QoL-R, as seen in this additional analysis of sub-
scales. There are also relationship issues to consider as
enrolment in this study and contact with research nurses
may have altered the sexual behaviour of these couples,
and control as well as emotional health may be import-
ant. Research nurses involved in this study reported thatrelationships can be improved by the involvement of
partners in the study. Further research into partner is-
sues relating to sexual dysfunction is required. Routine
consultations could include questions on ED as it has a
big impact on quality of life of sufferer and partner.
There is evidence to suggest that doctors need to sup-
port patients’ sexual activity as regular intercourse may
improve erectile function and quality of life [21]. This is
supported by our previous findings of a small positive
correlation between frequency of intercourse and IIEF
score [6].
Conclusions
We have evaluated the MED-QoL and produced the re-
vised MED-QoL-R with three identified subscales. Our
secondary analysis has shown a significant improvement
in sexual health related quality of life, specifically in rela-
tion to perception of control and emotional health in
men with untreated ED given 40 mg simvastatin for six
months. In addition our findings further demonstrate
that the number of reported encounters may have a
positive effect on perception of control over ED for men
treated with simvastatin. Therefore, women could also
be informed not only about the risks associated with ED
and later development of CVD but also about their part-
ners’ sexual health related quality of life and to encour-
age them to attend for medical assessment.
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